|
|
|
An association between a chemotherapy-induced hearing loss and specific genetic variants has been identified, according to a new study published online in Nature Genetics. The study suggests that these genetic variants may be useful to identify individuals with increased risk of chemotherapy-induced hearing loss, which could help to manage treatment.
Cisplatin is a commonly used chemotherapy drug, although its side-effects include serious hearing loss in 10-25% of adults and 41-61% of children. In order to identify genetic variants that may be associated with increased risk of cisplatin-induced hearing loss, Colin Ross and colleagues analyzed 220 drug-metabolism genes from over 150 children receiving cisplatin chemotherapy. The scientists found that in these children, variants in the genes TPMT and COMT are significantly associated with cisplatin-induced hearing loss. Further research is needed to determine whether these findings will be useful in guiding treatment options in a clinical setting. Author contact: Colin Ross (University of British Columbia, Vancouver, Canada)
E-mail: colinross1@gmail.com Abstract available online. (C) Nature Genetics press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|